Literature DB >> 7538847

Structure-function analysis of human IL-6: identification of two distinct regions that are important for receptor binding.

A Hammacher1, L D Ward, J Weinstock, H Treutlein, K Yasukawa, R J Simpson.   

Abstract

Interleukin-6 (IL-6) is a multifunctional cytokine that plays an important role in host defense. It has been predicted that IL-6 may fold as a 4 alpha-helix bundle structure with up-up-down-down topology. Despite a high degree of sequence similarity (42%) the human and mouse IL-6 polypeptides display distinct species-specific activities. Although human IL-6 (hIL-6) is active in both human and mouse cell assays, mouse IL-6 (mIL-6) is not active on human cells. Previously, we demonstrated that the 5 C-terminal residues of mIL-6 are important for activity, conformation, and stability (Ward LD et al., 1993, Protein Sci 2:1472-1481). To further probe the structure-function relationship of this cytokine, we have constructed several human/mouse IL-6 hybrid molecules. Restriction endonuclease sites were introduced and used to ligate the human and mouse sequences at junction points situated at Leu-62 (Lys-65 in mIL-6) in the putative connecting loop AB between helices A and B, at Arg-113 (Val-117 in mIL-6) at the N-terminal end of helix C, at Lys-150 (Asp-152 in mIL-6) in the connecting loop CD between helices C and D, and at Leu-178 (Thr-180 in mIL-6) in helix D. Hybrid molecules consisting of various combinations of these fragments were constructed, expressed, and purified to homogeneity. The conformational integrity of the IL-6 hybrids was assessed by far-UV CD. Analysis of their biological activity in a human bioassay (using the HepG2 cell line), a mouse bioassay (using the 7TD1 cell line), and receptor binding properties indicates that at least 2 regions of hIL-6, residues 178-184 in helix D and residues 63-113 in the region incorporating part of the putative connecting loop AB through to the beginning of helix C, are critical for efficient binding to the human IL-6 receptor. For human IL-6, it would appear that interactions between residues Ala-180, Leu-181, and Met-184 and residues in the N-terminal region may be critical for maintaining the structure of the molecule; replacement of these residues with the corresponding 3 residues in mouse IL-6 correlated with a significant loss of alpha-helical content and a 200-fold reduction in activity in the mouse bioassay. A homology model of mIL-6 based on the X-ray structure of human granulocyte colony-stimulating factor is presented.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7538847      PMCID: PMC2142761          DOI: 10.1002/pro.5560031213

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  56 in total

1.  Rapid and efficient site-specific mutagenesis without phenotypic selection.

Authors:  T A Kunkel; J D Roberts; R A Zakour
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

2.  Construction and functional analysis of hybrid interleukin-6 variants. Characterization of the role of the C-terminus for species specificity.

Authors:  F W Leebeek; D M Fowlkes
Journal:  FEBS Lett       Date:  1992-07-20       Impact factor: 4.124

3.  Saturation mutagenesis of the human interleukin 6 receptor-binding site: implications for its three-dimensional structure.

Authors:  R Savino; A Lahm; M Giorgio; A Cabibbo; A Tramontano; G Ciliberto
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

4.  Effect of semi-random mutagenesis at the C-terminal 4 amino acids of human interleukin-6 on its biological activity.

Authors:  H Yasueda; Y Miyasaka; T Shimamura; H Matsui
Journal:  Biochem Biophys Res Commun       Date:  1992-08-31       Impact factor: 3.575

5.  Involvement of the Arg179 in the active site of human IL-6.

Authors:  V Fontaine; R Savino; R Arcone; L de Wit; J P Brakenhoff; J Content; G Ciliberto
Journal:  Eur J Biochem       Date:  1993-02-01

6.  Role of leucine residues in the C-terminal region of human interleukin-6 in the biological activity.

Authors:  C Nishimura; T Ekida; K Nomura; K Sakamoto; H Suzuki; K Yasukawa; T Kishimoto; Y Arata
Journal:  FEBS Lett       Date:  1992-10-26       Impact factor: 4.124

7.  Identification of a receptor binding site in the carboxyl terminus of human interleukin-6.

Authors:  F W Leebeek; K Kariya; M Schwabe; D M Fowlkes
Journal:  J Biol Chem       Date:  1992-07-25       Impact factor: 5.157

8.  Purification and characterization of a recombinant murine interleukin-6. Isolation of N- and C-terminally truncated forms.

Authors:  J G Zhang; R L Moritz; G E Reid; L D Ward; R J Simpson
Journal:  Eur J Biochem       Date:  1992-08-01

9.  Direct association of interleukin-6 with a 130-kDa component of the interleukin-6 receptor system.

Authors:  F D'Alessandro; O R Colamonici; R P Nordan
Journal:  J Biol Chem       Date:  1993-01-25       Impact factor: 5.157

10.  A receptor-binding peptide from human interleukin-6: isolation and a proton nuclear magnetic resonance study.

Authors:  T Ekida; C Nishimura; S Masuda; S Itoh; I Shimada; Y Arata
Journal:  Biochem Biophys Res Commun       Date:  1992-11-30       Impact factor: 3.575

View more
  32 in total

1.  Engineering human interleukin-6 to obtain variants with strongly enhanced bioactivity.

Authors:  C Toniatti; A Cabibbo; E Sporena; A L Salvati; M Cerretani; S Serafini; A Lahm; R Cortese; G Ciliberto
Journal:  EMBO J       Date:  1996-06-03       Impact factor: 11.598

Review 2.  Involvement of pro- and anti-inflammatory cytokines and chemokines in the pathophysiology of traumatic brain injury.

Authors:  Jenna M Ziebell; Maria Cristina Morganti-Kossmann
Journal:  Neurotherapeutics       Date:  2010-01       Impact factor: 7.620

3.  Phenotype-information-phenotype cycle for deconvolution of combinatorial antibody libraries selected against complex systems.

Authors:  Hongkai Zhang; Ali Torkamani; Teresa M Jones; Diana I Ruiz; Jaume Pons; Richard A Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-08       Impact factor: 11.205

4.  Triglyceride-rich lipoprotein lipolysis products increase blood-brain barrier transfer coefficient and induce astrocyte lipid droplets and cell stress.

Authors:  Linda L Lee; Hnin H Aung; Dennis W Wilson; Steven E Anderson; John C Rutledge; Jennifer M Rutkowsky
Journal:  Am J Physiol Cell Physiol       Date:  2017-01-11       Impact factor: 4.249

5.  Exercise pre-conditioning reduces brain inflammation and protects against toxicity induced by traumatic brain injury: behavioral and neurochemical approach.

Authors:  Bibiana Castagna Mota; Leticia Pereira; Mauren Assis Souza; Luiz Fernando Almeida Silva; Danieli Valnes Magni; Ana Paula Oliveira Ferreira; Mauro Schneider Oliveira; Ana Flávia Furian; Leidiane Mazzardo-Martins; Morgana Duarte da Silva; Adair Roberto Soares Santos; Juliano Ferreira; Michele Rechia Fighera; Luiz Fernando Freire Royes
Journal:  Neurotox Res       Date:  2011-07-07       Impact factor: 3.911

6.  Detection of direct binding of human herpesvirus 8-encoded interleukin-6 (vIL-6) to both gp130 and IL-6 receptor (IL-6R) and identification of amino acid residues of vIL-6 important for IL-6R-dependent and -independent signaling.

Authors:  H Li; H Wang; J Nicholas
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

Review 7.  Cytokines as biochemical markers for knee osteoarthritis.

Authors:  Thomas Mabey; Sittisak Honsawek
Journal:  World J Orthop       Date:  2015-01-18

Review 8.  Interleukin-6: structure-function relationships.

Authors:  R J Simpson; A Hammacher; D K Smith; J M Matthews; L D Ward
Journal:  Protein Sci       Date:  1997-05       Impact factor: 6.725

Review 9.  The current progress in understanding the molecular functions and mechanisms of visfatin in osteoarthritis.

Authors:  Lele Liao; Yiyue Chen; Wanchun Wang
Journal:  J Bone Miner Metab       Date:  2016-03-11       Impact factor: 2.626

10.  In vitro and in vivo antitumor effects of the recombinant immunotoxin IL6(T23)-PE38KDEL in multiple myeloma.

Authors:  DE-Jun Guo; Jia-Shan Han; Yan-Song Li; Zeng-Shan Liu; Shi-Ying Lu; Hong-Lin Ren
Journal:  Oncol Lett       Date:  2012-05-25       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.